NeuroSense Therapeutics (NRSN) Institutional Ownership → This Wall Street stock prediction just went viral (From Chaikin Analytics) (Ad) Free NRSN Stock Alerts $1.20 +0.08 (+7.16%) (As of 05/15/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for NeuroSense Therapeutics (NASDAQ:NRSN)CurrentInstitutional OwnershipPercentage1.04%Number ofInstitutional Buyers(last 12 months)0Number ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$428.84K Get NRSN Insider Trade Alerts Want to know when executives and insiders are buying or selling NeuroSense Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Ad Chaikin AnalyticsThis Wall Street stock prediction just went viralPeople around the world follow 50-year Wall Street veteran Marc Chaikin for his surprisingly accurate stock predictions. And he just issued an urgent WARNING for some of the most popular stocks in U.S. history.Watch just the first 5 minutes of his new prediction NeuroSense Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/15/2023Armistice Capital LLC662,000$470K0.0%-47.7%6.051% 5/11/2023 Meitav Investment House Ltd.95,000$193K0.0%N/A0.868% (Data available from 1/1/2016 forward) NRSN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of NRSN shares? During the previous two years, the following institutional investors and hedge funds held shares of NeuroSense Therapeutics shares: Armistice Capital LLC ($470K), Meitav Investment House Ltd. ($193K).Learn more on NRSN's institutional investors. What percentage of NeuroSense Therapeutics stock is owned by institutional investors? 1.04% of NeuroSense Therapeutics stock is owned by institutional investors. Learn more on NRSN's institutional investor holdings. Which institutional investors have been buying NeuroSense Therapeutics stock? The following institutional investors have purchased NeuroSense Therapeutics stock in the last 24 months: Meitav Investment House Ltd. ($95K). How much institutional buying is happening at NeuroSense Therapeutics? Institutional investors have bought a total of 95,000 shares in the last 24 months. This purchase volume represents approximately $163.40K in transactions. Which NeuroSense Therapeutics major shareholders have been selling company stock? The following institutional investors have sold NeuroSense Therapeutics stock in the last 24 months: Armistice Capital LLC ($604K). How much institutional selling is happening at NeuroSense Therapeutics? Institutional investors have sold a total of 604,000 shares in the last 24 months. This volume of shares sold represents approximately $428.84K in transactions. Related Companies: TNXP Institutional Ownership EDSA Institutional Ownership VINC Institutional Ownership FLGC Institutional Ownership HUGE Institutional Ownership PIRS Institutional Ownership RDHL Institutional Ownership NERV Institutional Ownership PPBT Institutional Ownership KPRX Institutional Ownership This page (NASDAQ:NRSN) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden to Drop BOMBSHELL June 13th?Paradigm PressHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.